Compal highlights its affiliate network and global partnerships with academic institutions and pharmaceutical firms to build a scalable biotech AI platform that accelerates drug discovery workflows through quantum computing and AI.

ReAIX, powered by the NVIDIA NeMo Agent Toolkit and PhysicsNeMo, creates agent frameworks and physical environment parameters that bridge lab-scale processes to manufacturing-scale operations.

CG A-QX Docking combines NVIDIA CUDA-Q quantum simulations with GPU-accelerated simulated annealing to enable large-scale virtual screening in drug discovery, a method validated by Kaohsiung Medical University.

Vernus AI’s ReAIX platform fuses AI, quantum computing, and physical simulation to build digital twins for biopharma manufacturing, delivering high-precision simulations across small and large molecules, cell therapies, and formulations, with projects like Orient EuroPharma aimed at shortening R&D cycles and cutting costs.

NYCU College of Pharmaceutical Sciences is developing a generative AI model and validation workflow for antibody drug development, employing AI for sequence design, NVIDIA Boltz-2 NIM for structure prediction, and fine-tuned ESM-2 models for specificity, with experimental validation feedback loops.

A session titled Accelerating Drug Discovery Through Quantum AI and Supercomputing showcases a quantum‑AI hybrid approach that speeds molecular docking up to 3,500× and uses 30-qubit quantum optimization to improve binding-energy predictions for targets like Alzheimer’s, in collaboration with NVIDIA and academic partners under NSTC funding.

Compal Electronics showcases quantum technology and advanced AI at COMPUTEX 2026, presenting them as engines of the healthcare revolution and a comprehensive bio-medical ecosystem from de novo drug design to intelligent manufacturing.